I cannot comment.
The only thing is that “Dear health care professional” letters are accompanied as well by public advisories on the Health Canada website. So again, in terms of transparency, we are not just communicating this information through Health Canada. Health Canada will then decide whether there is a benefit to changing or altering to the point where substantial steps have to be taken to restrict the product. But the patient is also advised, so there is a way of communicating now.